
NovoSeven1 mg/vial
Novo Nordisk
Coagulation Factor VIIa [Eptacog Alfa] is a recombinant activated human coagulation factor VII used for hemostatic management under specialist supervision.
Coagulation Factor VIIa [Eptacog Alfa] is a recombinant activated human coagulation factor VII used for hemostatic management under specialist supervision. Indications are classified below by strength of evidence.
In all cases, Coagulation Factor VIIa [Eptacog Alfa] should be initiated and dosed only by, or in close consultation with, a hematologist experienced in bleeding disorder management, ideally coordinated with a hemophilia treatment center.
Dosing of Coagulation Factor VIIa [Eptacog Alfa] is individualized by indication, body weight, and severity/site of bleeding, and must be directed by a hematology specialist. Representative dosing is summarized below; refer to the approved product labeling and treating physician's protocol for the specific product used.
| Indication | Dose | Interval |
|---|---|---|
| Hemophilia A/B with inhibitors (bleeding episodes/surgery) | 90 mcg/kg IV bolus | Every 2 hours until hemostasis achieved, then interval may be increased |
| Acquired hemophilia | 70-90 mcg/kg IV bolus | Every 2-3 hours until hemostasis |
| Congenital Factor VII deficiency | 15-30 mcg/kg IV bolus | Every 4-6 hours until hemostasis |
| Glanzmann's thrombasthenia (platelet-refractory) | 90 mcg/kg IV bolus | Every 2 hours, minimum of 3 doses |
Administered as a slow intravenous bolus injection over approximately 2-5 minutes; see Administration and Reconstitution for preparation and injection technique, and Duration of Treatment for guidance on tapering.
Because Coagulation Factor VIIa [Eptacog Alfa] is used in seriously ill patients with bleeding disorders, distinguishing drug-related effects from the underlying condition can be difficult. Reported adverse effects include:
Coagulation Factor VIIa [Eptacog Alfa] is contraindicated in patients with known hypersensitivity to eptacog alfa or to any other component of the product, including possible trace residual proteins from the manufacturing process (such as mouse, hamster, or bovine protein, depending on the specific product) - hypersensitivity should be verified against the manufacturing process of the specific product dispensed.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.